Details of the Drug

General Information of Drug (ID: DMNSJFD)

Drug Name
INDORAMIN
Synonyms
INDORAMIN; Indoramine; 26844-12-2; Indoramina; Wy-21901; Indoraminum [INN-Latin]; Indoramine [INN-French]; Indoramina [INN-Spanish]; UNII-0Z802HMY7H; Baratol; EINECS 248-041-5; BRN 0494035; WY 21901; 0Z802HMY7H; CHEMBL279516; C22H25N3O; Benzamide, N-(1-(2-(1H-indol-3-yl)ethyl)-4-piperidinyl)-; 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole; JXZZEXZZKAWDSP-UHFFFAOYSA-N; N-(1-(2-Indol-3-ylethyl)-4-piperidyl)benzamide; N-(1-(2-(1H-Indol-3-yl)ethyl)-4-piperidinyl)benzamide; Benzamide, N-(1-(2-indol-3-ylethyl)-4-piperidyl)-; Benzamide, N
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Withdrawn from market [1]
ATC Code
C02CA02: INDORAMIN
C02CA: Alpha-adrenoreceptor antagonists
C02C: ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING
C02: ANTIHYPERTENSIVES
C: CARDIOVASCULAR SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 347.5
Logarithm of the Partition Coefficient (xlogp) 4.1
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 20 mL/min/kg [3]
Elimination
5% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 4.3 hours [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 8.223 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.15% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 4.9 L/kg [3]
Chemical Identifiers
Formula
C22H25N3O
IUPAC Name
N-[1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl]benzamide
Canonical SMILES
C1CN(CCC1NC(=O)C2=CC=CC=C2)CCC3=CNC4=CC=CC=C43
InChI
InChI=1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)
InChIKey
JXZZEXZZKAWDSP-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
33625
ChEBI ID
CHEMBL279516
CAS Number
26844-12-2
UNII
0Z802HMY7H
DrugBank ID
DB08950
TTD ID
D02LHR
INTEDE ID
DR0876
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor alpha-1D (ADRA1D) TT34BHT ADA1D_HUMAN Inhibitor [5]
Adrenergic receptor alpha-2B (ADRA2B) TTWM4TY ADA2B_HUMAN Inhibitor [5]
Adrenergic receptor alpha-2C (ADRA2C) TT2NUT5 ADA2C_HUMAN Inhibitor [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alpha-1A adrenergic receptor (ADRA1A) OTUIWCL5 ADA1A_HUMAN Protein Interaction/Cellular Processes [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hypertension
ICD Disease Classification BA00-BA04
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Adrenergic receptor alpha-2C (ADRA2C) DTT ADRA2C 1.76E-01 -0.06 -0.28
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 501).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
6 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
7 Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol. 1995 Jan 16;288(2):201-7. doi: 10.1016/0922-4106(95)90195-7.